logo
Are You Self-Sabotaging Your Hormone Therapy?

Are You Self-Sabotaging Your Hormone Therapy?

Yahoo6 days ago
If you've been navigating the ups and downs of estrogen in midlife, you've probably heard the names: estradiol, estrone and estriol—the three main types of estrogen in the body. But new research is turning the spotlight onto another form of estrogen that may play a bigger role than previously thought—2-hydroxyestrone, sometimes referred to as a 'protective' estrogen.
In a recent study published in Menopause: The Journal of The North American Menopause Society, researchers looked at how a naturally derived supplement called 3,3′-diindolylmethane (DIM), a compound found in vegetables like broccoli and Brussels sprouts, may help shift estrogen metabolism in a beneficial direction. Specifically, they found that DIM supplementation increased levels of 2-hydroxyestrone while reducing levels of 16α-hydroxyestrone, a form of estrogen some studies have linked to increased breast cancer risk.
More from Flow Space
Why Midlife Women Are More Likely to Experience This Painful GI Condition
So what does this mean for your hormones, your health and your hot flashes? Here's what experts say you should know about DIM, 'good' estrogens and the future of hormone support in midlife and beyond.
That 'Natural' Supplement Might Be Messing With Your Hormones
DIM is a compound your body produces when you digest cruciferous vegetables like broccoli, kale and cabbage. It's been turned into a supplement and heavily promoted online as a way to 'detox' estrogen, clear hormonal acne or 'balance' hormones during perimenopause and menopause. But in supplement form, you're often getting much higher doses than you'd ever get from eating vegetables, and that can affect how your body processes hormones like estrogen.
'I like to say estrogen is a 'use it and lose it' hormone meaning you want to get the benefit of the estrogen, but you don't want it lingering in the body longer than it needs to because then it starts to accumulate and cause issues,' Dr. Stephanie Wallman, medical director at The Lanby, tells Flow Space. 'For menopausal women, who don't have much naturally cycling estrogen, there is not as much estrogen around and therefore do not require DIM to help move estrogen out of the body.'
In other words, if you're using DIM during menopause, it may disrupt hormone balance rather than restore it, especially in women already dealing with fluctuating or low estrogen levels.
And for women using hormone therapy, you may be undermining your own treatment without realizing it.
That could explain sudden changes in how you feel—like hot flashes returning, mood dips or other symptoms flaring up again. Some experts also caution that while altering estrogen metabolism may reduce certain risks (like estrogen-sensitive cancer), the long-term effects of sustained DIM use—especially in high doses—haven't been well studied.
'Each woman is programmed through their genes and environmental factors to process (detoxify) estrogen differently,' says Wallman. 'If a woman is predisposed to hold on to estrogen more or to process it through a less desirable pathway, this will still happen during menopause.'
Other Side Effects of DIM
You've probably seen the promises: DIM will 'balance your hormones,' 'detox estrogen' and 'support healthy metabolism.' But what's actually happening under the surface is far more nuanced, and for women in midlife, it's worth a closer look.
For starters, DIM doesn't remove toxins.
'Detoxify sounds appealing, but it's not a scientific term here,' Dr. Neha Pathak, chief physician editor at WebMD, tells Flow Space. 'DIM doesn't remove anything from the body, it just changes how estrogen is broken down.'
That might be helpful in some cases, but it's not inherently good or bad; it depends on your body, your symptoms and your overall hormonal profile.
When estrogen is metabolized, it can take different 'routes' in the body. Some metabolites—like 2-hydroxyestrone—are considered gentler and possibly protective, while others—like 16α-hydroxyestrone—may be more active or linked to cancer risk. DIM pushes metabolism toward the former. But experts caution that we don't fully understand what those changes mean in the long run.
'It's more complex than just 'good' or 'bad' estrogen,' says Pathak. 'We still have a lot to learn about what these changes really mean for long-term health.'
Another gray area? Cancer prevention. While some studies suggest that certain estrogen breakdown patterns are associated with a lower risk of breast cancer, there's no strong evidence that taking DIM as a supplement will actually reduce your risk.
'That's still a big question mark,' says Pathak. 'We don't know if trying to manipulate estrogen metabolism in this way leads to better outcomes.'
Talk to Your Doctor Before Mixing Supplements with Hormone Therapy
Many women start taking DIM often without realizing it could impact their hormones in significant ways. And many never bring it up with their doctor. But that silence can be risky, even if you're not on hormone therapy.
'DIM works very well and has become very popular among supplements that women try on their own,' says Wallman. 'But it can also cause side effects that are not so obviously tied to taking DIM, so I certainly recommend that doctors understand what DIM is—and what you can expect to happen when someone starts using it.'
The issue is that DIM doesn't behave like a harmless vitamin. It influences how your body breaks down estrogen, sometimes shifting the balance of estrogen metabolites in unpredictable ways. That might be helpful in some situations, but it could also affect mood, sleep or energy levels, and even change how other medications or hormone therapies work.
'In my practice, no one walks out without me knowing everything about their hormones, so I'm certainly asking about DIM,' says Wallman. 'But many practitioners are not—and they should be.'
Before adding anything new to your wellness regimen, talk to your healthcare provider, ideally someone who's experienced with menopause, perimenopause or hormone health. The goal isn't just to get a green light, it's to make sure the supplement actually makes sense for your body, your symptoms and your treatment plan.
Pathak, suggests bringing a few key questions to your appointment:
Do I really need this?
Could it affect other medications or supplements I'm taking?
Can I get similar benefits from diet instead?
How will we track if it's helping—or doing more harm than good?
Because while DIM may support healthy hormone metabolism in certain situations, it's not a one-size-fits-all solution. Your needs in midlife are unique—and so is your hormonal landscape.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Yahoo

time14 minutes ago

  • Yahoo

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

Claims Data Fail to Accurately Identify MI Types
Claims Data Fail to Accurately Identify MI Types

Medscape

time16 minutes ago

  • Medscape

Claims Data Fail to Accurately Identify MI Types

TOPLINE: Clinical auditing reveals significant misclassification in administrative codes for myocardial infarction (MI), with only 39% of type 1 (T1MI) codes and 72% of type 2 (T2MI) codes for the condition accurately reflecting the true diagnosis, researchers found. Nearly half of patients coded for T1MI had T2MI, whereas 26% of T2MI codes represented myocardial injury. METHODOLOGY: Researchers identified 350 randomly sampled patients with T1MI codes and 350 patients with T2MI codes during inpatient encounters using the International Statistical Classification of Diseases and Related Health Problems-10th Revision. The analysis included patients aged 65 years and older from October 1, 2017, to May 9, 2024, within eight hospitals in the Mass General Brigham system. Using the 4th Universal Definition of MI, the researchers reviewed the clinical encounters to assess evidence of plaque erosion or thrombus vs oxygen demand-supply imbalance. A second physician review was conducted for 146 challenging and 146 nonchallenging cases. TAKEAWAY: Among the 350 patients coded as having had T1MI, clinical adjudication revealed 138 (39%) as correctly diagnosed; 159 (45%) in fact had T2MI, and 35 (10%) had myocardial injury. Of the 350 patients coded as having had T2MI, 251 (72%) were confirmed, four (1%) were found to have T1MI, and 91 (26%) had myocardial injury. A second physician review demonstrated a high degree of agreement with the initial review, with a 94% agreement in nonchallenging cases and 86% in challenging cases. Hospitals equipped with vs without cardiac catheterization laboratories showed significantly lower misclassification rates (43% vs 58%; P = .0298). IN PRACTICE: 'Among individuals assigned a T1MI claims code, nearly one half have T2MI and many others have myocardial injury; fewer than one half have true T1MI,' the researchers reported. 'Our results also confirm and extend previous work showing that among those with T2MI codes, slightly more than one half have true T2MI, with most of the misclassification related to myocardial injury rather than T1MI. This has critically important implications for epidemiology and public policy' related to acute myocardial infarction. SOURCE: The study was led by Andrea Martinez, MD, of the Department of Medicine at Massachusetts General Hospital, Boston. It was published online on July 21 in Journal of the American College of Cardiology. LIMITATIONS: The results may not be generalized to other hospital systems and countries, where patterns of misclassification might differ. The researchers noted external validity assessment across multiple healthcare systems and in countries that have already introduced International Classification of Diseases-11th revision coding would be beneficial. While patterns of misclassification might have changed over time, the analysis was intentionally restricted to the period when codes for both T1MI and T2MI were available. DISCLOSURES: The study received support through a grant to Jason Wasfy from the Massachusetts General Hospital Executive Committee on Research. Individual authors reported receiving other grants and support, including grants from industry. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Remember Ingenuity? NASA's proposed Skyfall mission takes it further in stunning video
Remember Ingenuity? NASA's proposed Skyfall mission takes it further in stunning video

Digital Trends

time16 minutes ago

  • Digital Trends

Remember Ingenuity? NASA's proposed Skyfall mission takes it further in stunning video

NASA's incredible Ingenuity helicopter spent nearly three flying across the surface of Mars, becoming the first aircraft to achieve powered, controlled flight on a planet other than Earth. After suffering damage to one of its blades in early 2024, Ingenuity was grounded for good, and now rests on the martian surface as a testament to technological innovation and the triumph of autonomous flight on another planet. In an exciting development, the plucky helicopter has now inspired Skyfall, a mission concept recently unveiled by Virginia-based AeroVironment (AV) and NASA's Jet Propulsion Laboratory (JPL), who worked together to develop the Ingenuity aircraft. As you can see in the video at the top of this page, the Skyfall mission is designed to deploy not one but six helicopters on Mars, each of which would fly off to explore various locations selected by NASA as potential landing spots for the first crewed mission to the red planet, which could take place in the 2030s. The gathered data could also help scientists learn more about Mars, contributing to the expanding database of information collected by other Mars vehicles such as the Perseverance and Curiosity rovers. The video shows the dramatic Skyfall Maneuver, described by AV as 'an innovative entry, descent, and landing technique whereby the six rotorcraft deploy from their entry capsule during its descent through the martian atmosphere.' With the helicopters flying down to the Mars surface under their own power, the Skyfall system would do away with the need for a landing platform, which is one of the most expensive parts of any Mars mission and also carries huge risk. Just like Ingenuity, each helicopter would be capable of operating autonomously, and beam high-resolution imagery back to Earth for analysis, allowing mission planners to select the best possible landing location for the first human mission. 'Skyfall offers a revolutionary new approach to Mars exploration that is faster and more affordable than anything that's come before it,' said William Pomerantz, head of space ventures at AV. 'Thanks to a true partnership between industry and government, we're expanding the unprecedented success of Ingenuity.' Pomerantz added that with six helicopters, 'Skyfall offers a low-cost solution that multiplies the range we would cover, the data we would collect, and the scientific research we would conduct, making humanity's first footprints on Mars meaningfully closer.' With NASA's first human missions in mind and the need to identify an ideal landing area, AV is already working with NASA's JPL in the hope of getting the green light for the mission before working toward a potential 2028 launch.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store